Vertical Flow Immunoassay Based on Carbon Black Nanoparticles for the Detection of IgG against SARS-CoV-2 Spike Protein in Human Serum: Proof-of-Concept
Biosensors · 2023
DOI: 10.3390/bios13090857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, 2023. Verfasst von Maria Kropaneva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Ecology and Genetics of Microorganisms, Ural Branch of Russian Academy of Sciences, 614081 Perm, Russia. Hauptthemen laut MEDLINE: COVID-19, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, The Government of Perm krai, the Russian Science Foundation and the Government of Perm Krai.
Abstract (Originalsprache)
Point-of-care tests play an important role in serological diagnostics of infectious diseases and post-vaccination immunity monitoring, including in COVID-19. Currently, lateral flow tests dominate in this area and show good analytical performance. However, studies to improve the effectiveness of such tests remain important. In comparison with lateral flow tests, vertical flow immunoassays allow for a reduction in assay duration and the influence of the hook effect. Additionally, the use of carbon black nanoparticles (CNPs) as a color label can provide a lower detection limit (LOD) compared to conventional colloidal gold. Therefore, we have developed a vertical flow immunoassay for the detection of IgG against SARS-CoV-2 spike protein in human serum samples by applying a conjugate of CNPs with anti-human IgG mouse monoclonal antibodies (CNP@MAb). The vertical flow assay device consists of a plastic cassette with a hole on its top containing a nitrocellulose membrane coated with spike protein and an absorbent pad. The serum sample, washing buffer, and CNP@MAb flow vertically through the nitrocellulose membrane and absorbent pads, reducing assay time and simplifying the procedure. In positive samples, the interaction of CNP@MAb with anti-spike antibodies leads to the appearance of black spots, which can be visually detected. The developed method allows for rapid visual detection (5–7 min) of IgG vs. spike protein, with a LOD of 7.81 BAU/mL. It has been shown that an untrained operator can perform the assay and visually evaluate its results. Thus, the presented assay can be used in the further development of test systems for the serological diagnostics of COVID-19 or post-vaccination immunity monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Ecology and Genetics of Microorganisms, Ural Branch of Russian Academy of Sciences, 614081 Perm, Russia.
- Biology Faculty, Perm State University, 614990 Perm, Russia.
- Institute of Technical Chemistry, Ural Branch of Russian Academy of Sciences, 614013 Perm, Russia.
ORCID-Profile: Maria Kropaneva, Pavel Khramtsov, Sergey Lazarev, Dmitriy Kiselkov
Förderung
- Russian Science Foundation
- The Government of Perm krai
- the Russian Science Foundation and the Government of Perm Krai
Zitieren
APA
Kropaneva, M., Khramtsov, P., Bochkova, M., Lazarev, S., Kiselkov, D., & Rayev, M. (2023). Vertical Flow Immunoassay Based on Carbon Black Nanoparticles for the Detection of IgG against SARS-CoV-2 Spike Protein in Human Serum: Proof-of-Concept. Biosensors. https://doi.org/10.3390/bios13090857
Vancouver
Kropaneva M, Khramtsov P, Bochkova M, Lazarev S, Kiselkov D, Rayev M. Vertical Flow Immunoassay Based on Carbon Black Nanoparticles for the Detection of IgG against SARS-CoV-2 Spike Protein in Human Serum: Proof-of-Concept. Biosensors. 2023. doi:10.3390/bios13090857
BibTeX
@article{Kropaneva2023,
author = {Kropaneva, Maria and Khramtsov, Pavel and Bochkova, Maria and Lazarev, Sergey and Kiselkov, Dmitriy and Rayev, Mikhail},
title = {Vertical Flow Immunoassay Based on Carbon Black Nanoparticles for the Detection of IgG against SARS-CoV-2 Spike Protein in Human Serum: Proof-of-Concept},
journal = {Biosensors},
year = {2023},
doi = {10.3390/bios13090857}
}
EUVIMED